Cimlanod

Cimlanod
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name N-Hydroxy-5-methylfuran-2-sulfonamide;
CAS Number	1620330-72-4;
PubChem CID	76685198;
DrugBank	DB14983;
UNII	2US4FK1EPV;
Chemical and physical data
Formula	C5H7NO4S
Molar mass	177.17 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1=CC=C(O1)S(=O)(=O)NO;

Cimlanod (development codes CXL-1427 and BMS-986231) is an experimental drug for the treatment of acute decompensated heart failure. It was discovered by Cardioxyl Pharmaceuticals, which was acquired by Bristol-Myers Squibb. It is a nitroxyl donor.[1]

Cimlanod is a prodrug of CXL-1020.[2]

A preliminary study showed efficacy in patients with class III and IV heart failure.[3] A phase II clinical trial was completed in 2016.[4]

References

"BMS 986231". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22. Alternative Names: BMS-986231; CXL 1427; HNO Donor
"CXL 1020". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22.
Zoler ML (22 May 2016). "Nitroxl prodrug shows promise in acute heart failure".
Clinical trial number NCT02157506 for "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure" at ClinicalTrials.gov

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "BMS 986231". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22. Alternative Names: BMS-986231; CXL 1427; HNO Donor

[2] "CXL 1020". AdisInsight. Springer Nature Switzerland AG. Retrieved 2017-05-22.

[3] Zoler ML (22 May 2016). "Nitroxl prodrug shows promise in acute heart failure".

[4] Clinical trial number NCT02157506 for "A Dose Ranging Phase IIa Study of 6 Hour Intravenous Dosages of CXL-1427 in Patients Hospitalized With Heart Failure" at ClinicalTrials.gov